How we’re helping in Eswatini

Continuing the battle against tuberculosis and HIV

A support group at Matsanjeni clinic, in Eswatini’s Shiselweni region, where MSF is working with the Ministry of Health to provide community-based care to people living with HIV and tuberculosis.
Estwatini 2018 © Fanny Hostettler/MSF
Click to hide Text

Learn more about how we are responding to the coronavirus pandemic in Eswatini. 

Despite the decrease in the number of new infections and deaths from HIV and tuberculosis (TB) in Eswatini (formerly Swaziland), controlling the spread remains a challenge.

One-third of adults in Eswatini are HIV positive, which also increases their vulnerability to TB and other infections. In this context, Doctors Without Borders/Médecins Sans Frontières (MSF) continued to assist the Ministry of Health with prevention and care in Shiselweni region in 2018, while handing over some long-term activities to the ministry and partner organizations, such as our project in Manzini region, which began as an emergency intervention in 2010.

received first-line ARV treatment in 2018
received second- and third-line ARV treatment
started treatment for TB, including 45 for DR-TB

Our emphasis in Eswatini is on community-based, patient- centered models of care and what is known as a ‘test and start’ strategy, which involves initiating antiretroviral (ARV) treatment at the time of diagnosis, irrespective of clinical criteria.

We offer community-based testing for HIV and TB, oral HIV self-testing for hard-to-reach groups such as sex workers and men who have sex with men, and pre-exposure prophylaxis (PrEP) for people at increased risk of HIV infection. A total of 5,296 people accessed HIV self-testing and 468 were initiated on PrEP in 2018.


MSF projects in Eswatini

View map

Our teams provide specialized, integrated care for people living with HIV, including second- and third-line ARV therapy for those whose previous treatment has failed to work, and point-of-care screening and treatment for other diseases, such as cervical cancer, drug-resistant TB, and cryptococcal meningitis, which commonly occur in people living with HIV. 

In 2018, 1,610 women were screened for cervical cancer, of whom 8 percent tested positive. Of these, 67 percent were treated. We provided prophylactic treatment for cryptococcal meningitis to 26 patients.

Join the MSF movement to help in Eswatini and other countries